Showing 3771-3780 of 9336 results for "".
- Genital Psoriasis Consensus Offers Age-Specific Roadmap for Clinical Carehttps://practicaldermatology.com/news/genital-psoriasis-consensus-offers-age-specific-roadmap-for-clinical-care/2487330/A new expert consensus manuscript in the American Journal of Clinical Dermatology offered recommendations aimed at improving the diagnosis and management of genital psoriasis, according to a press release from Arcutis. The publication represents the second manuscript, Arcutis said
- Skin Cancer Champions Announces Patient Advocacy Summithttps://practicaldermatology.com/news/skin-cancer-champions-announces-patient-advocacy-summit/2487322/The inaugural Patient Advocacy Summit, hosted by Skin Cancer Champions, will be held on October 30, 2026, at The Fairmont Copley Plaza in Boston, Massachusetts, the organization announced. “The Summit is an important milestone in our mission of providing support, advocacy, and amplifying t
- Analysis: Capecitabine Shows Clinical Activity in Advanced Head and Neck Cutaneous SCChttps://practicaldermatology.com/news/neoadjuvant-capecitabine-yields-42-complete-pathologic-response-rate-in-advanced-cscchn/2487303/Neoadjuvant capecitabine demonstrated encouraging clinical and pathologic responses in patients with advanced cutaneous squamous cell carcinoma of the head and neck (cSCCHN), according to findings from a prosp
- Rubedo Reports Early Clinical Activity for GPX4 Modulator RLS-1496 in Actinic Keratosishttps://practicaldermatology.com/news/rubedo-reports-early-clinical-activity-for-gpx4-modulator-rls-1496-in-actinic-keratosis/2487263/Rubedo Life Sciences announced preliminary findings from a Phase 1b/2a trial evaluating topical RLS-1496 1% cream in adults with actinic keratosis (AK), reporting reductions in lesion counts alongside favorable tolerability data. The interim findings were presented at the RBC Capital Markets Glob
- Analysis: Pediatric Allergic Rhinitis Doubled in Japan Over 40 Yearshttps://practicaldermatology.com/news/analysis-pediatric-allergic-rhinitis-doubled-in-japan-over-40-years/2487238/A 40-year epidemiologic analysis published in the World Allergy Organization Journal showed an increases in allergic rhinitis (AR), allergic conjunctivitis (AC), and Japanese cedar pollinosis (JCP) among school-aged children in western Japan, while rates of atopic dermatitis (AD) and bro
- PanOxyl Portfolio Highlights Accessibility and Long-Term Acne Management During Virtual Desksidehttps://practicaldermatology.com/news/panoxyl-portfolio-highlights-accessibility-and-long-term-acne-management-during-virtual-deskside/2487257/Acne management requires a broader approach than simply targeting active breakouts, according to speakers during a virtual media deskside hosted by Revance. The discussion focused on over-the-counter acne management strategies with the PanOxyl brand as well as procedural options for acne scar tre
- Swiftscope App Integrates Dermatoscopy With SwiftPro Wart Treatmentshttps://practicaldermatology.com/news/swiftscope-app-integrates-dermatoscopy-with-swiftpro-wart-treatments/2487231/Emblation has launched the Swiftscope app, a new digital imaging platform designed to help clinicians visually monitor treatment progress in patients undergoing SwiftPro microwave therapy for common and plantar warts, according to a news release. The announcement f
- Review: Botulinum Toxin Shows Potential in Acne Treatmenthttps://practicaldermatology.com/news/systematic-review-highlights-botulinum-toxins-potential-in-acne-treatment/2487204/Botulinum toxin A may offer a potential adjunctive treatment option for both acne vulgaris and acne scarring, according to a recent systematic review published in the Journal of Drugs in Dermatology. Botulinum Toxin S
- FDA Approves OTC Switch for Galderma’s Differin Epiduo Acne Gelhttps://practicaldermatology.com/news/fda-approves-otc-switch-for-galdermas-differin-epiduo-acne-gel/2487203/The US Food and Drug Administration (FDA) has approved Galderma’s Differin Epiduo Acne Gel (adapalene 0.1% and benzoyl peroxide 2.5%) for over-the-counter (OTC) use in patients aged 12 years and older, marking a notable prescription-to-OTC transition in acne therap
- Randomized Trial Evaluates Educational Delivery Methods for Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/randomized-trial-evaluates-educational-delivery-methods-for-pediatric-atopic-dermatitis/2487170/A randomized controlled trial published online in Pediatric Dermatology found that video-based therapeutic patient education (TPE) did not significantly outperform standard educational handouts for pediatric atopic dermatiti